Avandia

GlaxoSmithKline Plc and Takeda Pharmaceutical Co. Ltd. said they are unlikely to build in-house diagnostic divisions like Roche Holding AG, which is bidding to take over a U.S. maker of gene-mapping tools. The tandem of diagnostics and therapeutics is a logical tandem and will be very important in the future, said Tachi Yamada, chief medical and scientific officer of Osaka, Japan- based Takeda, in...  

Pharmaceutical giant GlaxoSmithKline has agreed to settle several product liability cases involving its blockbuster diabetes drug Avandia, spokeswoman Bernadette King confirmed Thursday. The company will make payments out of cash already designated to claims involving Avandia. GlaxoSmithKline (NYSE: GSK), which has been facing legal issues relating to Avandia for years, has its North American headquarters in Research Triangle Park and employs...  

Nadrich & Cohen, LLP reports that GlaxoSmithKline has agreed to settle approximately 20,000 Avandia side effects lawsuits. Los Angeles, CA, February 3, 2012 – UK drug-maker GlaxoSmithKline has agreed to settle 20,000 Avandia side effects lawsuits. According to a Bloomberg  

GlaxoSmithKline Plc (GSK), which is paying $3 billion to resolve government claims that it illegally marketed drugs such as the Avandia diabetes medication, agreed to settle more lawsuits over the pills, a lawyer said. Glaxo, the U.K.’s ...  

GlaxoSmithKline Plc (GSK), which is paying $3 billion to resolve government claims that it illegally marketed drugs such as the Avandia diabetes medication, agreed to settle more lawsuits over the pills, a lawyer said. Glaxo, the U.K.s biggest drugmaker, agreed last month to resolve more than 20,000 cases alleging Avandia causes heart attacks, said Paul Kiesel, a lawyer for former users. The accord...  

Overall, Glaxo's U.S. sales declined 5% for 2011, excluding the effects of currency exchange, partly because of generic competition for herpes ... television ads for erectile-dysfunction drug Levitra out of respect for the sensitivities of TV viewers.  

I return to the topic of GlaxoSmithKline (GSK.L) following its 2011 results and because I am thinking of buying it for the £10,000 portfolio based on Citywire Top Stocks®. Some think this focus on big, blue chips is a bit boring, but I think ...  

GlaxoSmithKline plc suspended enrollment in four trials of an Anacor Pharmaceuticals Inc. antibiotic after a “microbiological finding” in some patients in one of the studies. The stock of Palo Alto-based Anacor (NASDAQ: ANAC) was down 36 cents, or nearly 5 percent, to $7.06 per share by mid-afternoon, after GSK said Monday that it suspended enrollment around GSK-052 in patients with complicated urinary tract infections. The finding isn’t...  

GlaxoSmithKline said it earned $8.3 billion in net profit in 2011, up from $2.6 billion in 2010, thanks to restructuring of the London-based pharmaceutical company that has extensive operations in Pennsylvania. Revenues were down to $43.4 billion in 2011 compared to almost $45 billion in 2010. GlaxoSmithKline is one of the top 25 foreign-owned companies with business in southwestern Pennsylvania. It has 258 employees at its GlaxoSmithKline...  

Feb. 8 (Bloomberg) -- GlaxoSmithKline Plc is testing a capsule-based inhaler, suggesting the U.K.’s biggest drugmaker is developing a cheaper version of its best-selling asthma treatment to compete with generic versions. Glaxo completed a 60 ...  

British drugmaker GlaxoSmithKline said Tuesday that net profits more than tripled in 2011 compared with the previous year, as large efficiency savings offset falling revenues.Earnings after tax surged to £5.261 billion (6.34 billion euros, $8.32 billion) in 2011, which compared with £1.634 in the previous year, GSK said in a results statement.  

GlaxoSmithKline Plc (GSK.L) is getting more bang for its buck in drug research, underpinning expectations for a return to sales and margin growth despite fourth-quarter results that fell short of analyst forecasts. Britain's biggest drugmaker said on Tuesday it had lifted financial returns from its laboratories to an estimated 12 percent, from 11 percent two years ago, and was confident of reaching...  

GlaxoSmithKline Plc (GSK), the U.K.s largest drugmaker, is seeking an acquisition in Turkey as it struggles to become profitable in the country, Hurriyet said, citing the companys emerging markets president. Potential targets include producers of cardiovascular drugs or businesses with production facilities that would add value to Glaxos operations, Hurriyet cited Abbas Hussain as saying. Glaxo...  

GlaxoSmithKline's plans for reconfiguring its research-and-development efforts aim to boost cost-effectiveness without reducing the number of scientists in Research Triangle Park or elsewhere, said a company spokeswoman.Click to Continue »  

GlaxoSmithKline Plc, Eli Lilly & Co. and Pfizer Inc. are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said.